Log In or Register to Join The Conversation!

Biogen, Ionis to Continue SMA Therapy Development Partnership

This topic has 0 replies, 1 voice, and was last updated 2 years, 5 months ago by Michael Nace.

  • Author
    Posts
    • #10936
      Michael Nace
      Keymaster

      Biogen and Ionis recently announced in a press release that the two companies will continue to partner in developing therapies for SMA. The partnership yielded the development and launch of Spinraza — a landmark therapy for treating the disease. A quick look at Ionis’ pipeline doesn’t show any other SMA therapies in development, however, the company is working on indications that bear some similarity to the disease, such as <span style=”color: #000000; font-family: ‘Open Sans’, sans-serif; font-size: 14px; background-color: #f2f2f2;”>IONIS-SOD1</span><span style=”border: 0px; font-family: ‘Open Sans’, sans-serif; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline; font-size: 10.5px; height: 0px; line-height: 0; position: relative; top: 0.5ex; color: #000000;”>Rx,</span> which is being developed with Biogen for ALS.

      It will be interesting to see what the next steps are for the two companies in advancing SMA therapies, particularly with AveXis looking like they are getting closer with AVXS-101.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2020 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Copyright © 2017-2020 All rights reserved.